Adding lenvatinib and pembrolizumab to TACE improves progression-free survival in liver cancer, but the trial’s overall-survival goal was not met

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

Adding the targeted therapy lenvatinib and the immunotherapy pembrolizumab to transarterial chemoembolization (TACE, a procedure that delivers chemotherapy directly into the blood vessels feeding a liver tumor) significantly extended progression-free survival compared with TACE plus two placebos, in adults with unresectable, non-metastatic, intermediate-stage hepatocellular carcinoma (the most common form of liver cancer), in the randomized, double-blind, phase 3 LEAP-012 trial (ClinicalTrials.gov NCT04246177; first interim results published in The Lancet, DOI 10.1016/S0140-6736(24)02575-3). Median progression-free survival was 14.6 months with the triple combination versus 10.0 months with TACE alone (hazard ratio 0.66; P=0.0002) — a real, statistically significant benefit. However, at this same interim analysis the trial’s co-primary endpoint of overall survival did NOT reach statistical significance (2-year overall-survival rate 75% versus 69%; hazard ratio 0.80; P=0.087), and subsequent reporting indicates the trial is being closed because a future analysis was judged unlikely to reach the pre-specified overall-survival threshold. This drug combination does not currently hold FDA approval for this indication in the United States (a related regulatory filing reportedly gained approval in China in 2025, not independently confirmed against a primary regulatory record).

What This Means

In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with intermediate-stage, unresectable liver cancer — a real, statistically significant result on this endpoint.

What This Doesn't Mean

The trial's co-primary endpoint of overall survival did NOT reach statistical significance at this interim analysis, and subsequent reporting indicates the study is being closed because a future analysis was judged unlikely to reach the pre-specified survival threshold. This must not be presented as a confirmed survival benefit or as an FDA-approved combination in the United States — it is a real, positive result on one endpoint (progression-free survival) alongside a real, disclosed miss on the other (overall survival), not a simple win.

Why It Matters

Even though this specific trial's overall-survival goal was not met, a statistically significant progression-free-survival improvement in a large, randomized, global phase 3 trial is real evidence worth recording honestly — including the parts that did not go as hoped, consistent with this project's "What Did Not Work" framing for real, mixed, or discontinued results.

Promise & Proof

Proof — strength of the evidence 4 / 5
  • Base score from evidence stage: Later-Stage Human.
Promise — potential significance if later evidence holds up 4 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.
  • Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with unresectable, non-metastatic, intermediate-stage hepatocellular carcinoma (liver cancer) without extrahepatic spread or vascular invasion, randomized to transarterial chemoembolization (TACE) plus lenvatinib plus pembrolizumab, or TACE plus dual placebo, at 137 sites across 33 countries. (Adults)

Not an FDA-approved combination in the United States as of this review; readers should not seek this specific triple combination as an approved liver-cancer treatment. Overall-survival data remain immature and the trial is reportedly being closed — this record should be re-checked against the final published results before any future republication.

Full evidence details
Study design
Randomized controlled trial
Sample size
480

Funding & Conflicts

Trial sponsors: Merck (pembrolizumab's manufacturer) and Eisai (lenvatinib's manufacturer) — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

Adding lenvatinib and pembrolizumab to TACE improves progression-free survival in liver cancer, but the trial’s overall-survival goal was not met

https://cancerdiscoveries.com/discoveries/adding-lenvatinib-and-pembrolizumab-to-tace-improves-progression-free-survival-in-liver-cancer-but-the-trials-overall-survival-goal-was-not-met/

Evidence stage: Later-Stage Human

What This Means

In the randomized, double-blind, phase 3 LEAP-012 trial, adding lenvatinib and pembrolizumab to TACE significantly extended progression-free survival compared with TACE alone (14.6 months versus 10.0 months) in patients with intermediate-stage, unresectable liver cancer — a real, statistically significant result on this endpoint.

What This Doesn't Mean

The trial's co-primary endpoint of overall survival did NOT reach statistical significance at this interim analysis, and subsequent reporting indicates the study is being closed because a future analysis was judged unlikely to reach the pre-specified survival threshold. This must not be presented as a confirmed survival benefit or as an FDA-approved combination in the United States — it is a real, positive result on one endpoint (progression-free survival) alongside a real, disclosed miss on the other (overall survival), not a simple win.

Why It Matters

Even though this specific trial's overall-survival goal was not met, a statistically significant progression-free-survival improvement in a large, randomized, global phase 3 trial is real evidence worth recording honestly — including the parts that did not go as hoped, consistent with this project's "What Did Not Work" framing for real, mixed, or discontinued results.

Primary sources

  • LEAP-012: transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (The Lancet) — https://doi.org/10.1016/S0140-6736(24)02575-3 (DOI 10.1016/S0140-6736(24)02575-3)

Date verified: 2026-08-13

Correction status: No correction or retraction